About me
Dr. Mei Sheng Duh, M.P.H., Sc.D., is a Managing Principal and Chief Epidemiologist at Analysis Group. She specializes in decision-grade real-world evidence (RWE) to support product registration, post-approval safety and effectiveness studies, and health technology assessments of pharmaceuticals, vaccines, and regenerative biotherapeutics. Dr. Duh has led numerous RWE programs supporting NDA and BLA submissions to the FDA and product label expansion applications to the FDA and the European Medicines Agency. She holds a Doctor of Science in pharmacoepidemiology from the Harvard T.H. Chan School of Public Health, where she is an adjunct researcher in biostatistics, and a Master of Public Health from Yale School of Medicine.
